Overview

Study to Evaluate the Relative Bioavailability of Varenicline Administered as OC-01 (Varenicline) Nasal Spray as Compared to Varenicline Administered Orally as Chantix®

Status:
Completed

Trial end date:
2019-11-15

Target enrollment:

Participant gender:

Summary

To assess the relative bioavailability of varenicline administered intranasally at its highest intended clinical strength compared to varenicline administered orally at its highest oral tablet strength.

Phase:

Phase 1

Details

Lead Sponsor:

Oyster Point Pharma, Inc.

Treatments:

Varenicline